Researchers sought to determine the significance of short-term blood pressure variability for assessing CTR-CVT in patients with multiple myeloma undergoing treatment with proteasome inhibitors.

Oncology Small Molecule Drugs Market Expected to Grow Significantly Due to Industry Advancements. Growing Demand for Personalized Medicine and Target ...

Inc. , today announced a definitive merger agreement under which Bristol Myers Squibb ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash ...

Native gel electrophoresis revealed a higher proportion of doubly-capped 26S proteasome (19S-20S-19S) in the cortex than in the liver or kidney. To investigate the interplay between proteasome ...

There was a median response time of 30 days and the median duration of response was 11 months for all responders and 19 months for those with the strongest responses. The safety profile included ...

A German court ruled that Pfizer and BioNTech infringed Moderna's COVID-19 vaccine patent ... at least three prior therapies, ...

Results Upon proteasome inhibition, disease activity significantly declined ... during the treatment period (see online supplementary table S3). In total, 19 AEs were reported during the treatment ...